A 3-decade multicenter European experience with cladribine as upfront treatment in 384 patients with hairy cell leukemia
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2022007854
Abstract: Key Points Cladribine is regarded as the first treatment of choice for symptomatic hairy cell leukemia. This large international study reports a complete response in 72% of cases and a continuous complete response in 20%… read more here.
Keywords: hairy cell; cladribine; decade multicenter; cell leukemia ... See more keywords